Listen to this roundtable discussion with Dr William J Gradishar, Dr Virginia Kaklamani, Dr Erica Mayer and Dr Seth Wander, moderated by Dr Neil Love, on the use of ovarian function suppression/ablation as a therapeutic strategy for patients with HR-positive breast cancer. https://bit.ly/4cjTIUL
Research To Practice’s Post
More Relevant Posts
-
Vanessa Sheppard, Ph.D. led a team of researchers, including SOPH’s Fariha Tariq, M.P.H, and Malik Phillips, M.P.H., to evaluate the trust in oncology providers in a racial/ethnically diverse group of cancer patients. Their study was just published in Clinical Breast Cancer. Read it here: https://lnkd.in/eVyPcmMZ
-
-
Head of DP, Operations | Strategic Operations Professional | Global Leadership | Process Optimization | Training & Development
WEBINAR RECORDING: Hear breast cancer expert from Ipsos, Eric Blouin, and CEO of Living Beyond Breast Cancer, Jean Sachs, dive into the findings and implications of new research highlighting the time-burden patients with ER+, HER2- mBC face when attending appointments, and their experiences and treatment preferences. https://lnkd.in/gzKYEsy9
-
-
WEBINAR RECORDING: Hear breast cancer expert from Ipsos, Eric Blouin, and CEO of Living Beyond Breast Cancer, Jean Sachs, dive into the findings and implications of new research highlighting the time-burden patients with ER+, HER2- mBC face when attending appointments, and their experiences and treatment preferences. https://lnkd.in/ehgidmbu
-
-
NTRK gene fusions are rare alterations in the general breast cancer population (<1%) but, if present, may represent a target for treatment with TRK inhibitors, like larotrectinib In San Antonio, Cristiano de Pádua Souza and I discussed this topic and some new results from #SABCS24 👇🏻 OncoAlert
Join our collaborators at Oncobites.tv https://lnkd.in/dMTRTVkd interview featuring Cristiano de Pádua Souza as he shares research on larotrectinib as an effective treatment for TRK fusion breast cancer. Dr. Elisa Agostinetto from the Jules Bordet Institute in Brussels interviews Dr. Souza, discussing the safety and impact of this therapy.
-
-
ICYMI: In this episode of OncLive On Air, Ryan Merkow, MD, MS, of the University of Chicago Medicine Comprehensive Cancer Center, and Louise Catherine Connell, MB BCh BAO, BMedSc, of Memorial Sloan Kettering Cancer Center, discuss the use of HAI therapy for patients with colorectal cancer. https://lnkd.in/eZsDpEin
-
-
🌟Excited to share the #Review 'Insight into the Crosstalk between Photodynamic Therapy and Immunotherapy in Breast Cancer' ✍️By Hongzhong Jin, Shichong Liao, et al. 🔗Find the full paper here: https://lnkd.in/dJ-FcJV8 Keywords: #breastcancer; T cell; macrophage
-
-
In collaboration with Repare Therapeutics, our novel work here demonstrates the efficacy of novel cell cycle target-PKYMT1 using a selective inhibitor RP-6306 and future combinations in tumors with high Cyclin expression. MYTHIC trial (https://lnkd.in/gBD5nmTM)
A study led by our Dr. Khandan Keyomarsi highlights the therapeutic potential of PKMYT1 inhibitors for patients with triple-negative breast cancer. Learn about this and other new MD Anderson research. #CancerResearch #EndCancer
-
Novartis at #ESMOBreast24 Visit poster 277P presented by Dr. Nadia Harbeck to learn more about our results on a descriptive analysis of hepatic safety in patients with HR+/HER2- breast cancer. https://lnkd.in/dgyBz9py #Novartis #BreastCancer
-
-
📜Check out the #Review "HER2 Intratumoral Heterogeneity in Breast Cancer, an Evolving Concept" ✍by Yanjun Hou (Atrium Health Wake Forest Baptist) et al. Find the full paper here▶️ https://lnkd.in/dN_aKtuE Keywords: HER2; breast cancer; heterogeneity
-
-
Learn about the most common types of breast cancer, along with rarer forms and an overview of metastatic breast cancer, a major BCRF research priority. https://bit.ly/3zZ4EZV
Types of Breast Cancer | BCRF
